We are monitoring the impact of COVID-19 on APAC Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1115
Share on
Share on

Asia Pacific Antibodies Market Research Report – Segmented By Product Type, Indication, End User, Application & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Forecast, Growth (2020 to 2025)

Pulished: February, 2020
ID: 1115
Pages: 145

The Asia Pacific Antibodies Market Size (2020 to 2025)

The size of the Antibodies Market in the Asia Pacific was valued at USD 12.95 Billion in 2020. This value is estimated to reach USD 20.73 Billion by the end of 2025, showcasing a growing potential of 9.87% CAGR during the forecast period.

The APAC region has the fastest growth rate of antibodies market in the world. The chronic disease burden of the region is increasing; thus, there is a rise in the research of monoclonal antibodies. The technological advancements and progressive R&D in the field of antibodies taking place in the Asia Pacific countries like India, China, Japan, and Australia are majorly expected to propel the market growth. Antibodies are used in research to develop new diagnoses and treatment for rare diseases and to study different biomarkers of different conditions. There is significant adoption of the therapeutic antibodies in this region, and the regulatory bodies in the area also have approved the treatment at a fast track without affecting safety. There are many antibody products in the clinical trials in the region, and the research been going in this region to create a vaccine for COVID-19 by using the antibody resistant to coronavirus.

The cost of antibody treatment is high, and the process is complex, which is restraining the Asia Pacific market growth to some extent. There are some side effects of the antibodies treatment like an allergic reaction, flu-like symptoms, vomiting, diarrhea, and low blood pressure, which is predicted to display a negative impact on the market to a limited extent. Less awareness in undeveloped countries is further degrading the market growth. 

This research report has been segmented and sub-segmented into the following categories:

  • By Product Type:  Monoclonal Antibodies, Polyclonal Antibodies, Anti-body drug complexes.
  • By Indication: Cancer, Autoimmune diseases, Infectious diseases, cardiovascular diseases, CNS disorders, others.
  • By End User: Hospitals/Clinics, Research Institute, Diagnostics Laboratories.
  • By Application: Medical, Experimental.
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC.

Regionally, the Indian antibodies market is growing at the highest rate in this region. The National Institute of Immunology (NII) has generated monoclonal antibodies for the detection of typhoid fever and hepatitis B virus. NII is also developing monoclonal antibodies against rotavirus and virulent strains of E. coli. 

Chinese antibodies market was leading the Asia Pacific market in 2019. China has many institutes that are researching antibodies. China is trying to develop a vaccine for COVID-19.

The Japanese government is promoting the production of biosimilar using antibodies. Japan has also developed antibodies for anti-glycosaminoglycan.

Most promising companies operating in the APAC Antibodies Market Profiled in the Report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly and company, A.G. Scientific, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, AbbVie Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Shimadzu Corporation (Japan)                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Takara Bio, Inc. (Japan)                         

                9.7 Levena Biopharma (China)                   

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Bio-Rad Laboratories, Inc. (U.S.)                     

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Asia-Pacific Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  2. Asia-Pacific Monoclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  3. Asia-Pacific Polyclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  4. Asia-Pacific Antibody-Drug complexes Market, By Region, From 2020 to 2025 (USD Million)
  5. Asia-Pacific Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  6. Asia-Pacific Cancer Market, By Region, From 2020 to 2025 (USD Million)
  7. Asia-Pacific Auto immune diseases Market, By Region, From 2020 to 2025 (USD Million)
  8. Asia-Pacific infectious diseases Market, By Region, From 2020 to 2025 (USD Million)
  9. Asia-Pacific Cardiovascular diseases Market, By Region, From 2020 to 2025 (USD Million)
  10. Asia-Pacific CNS disorders Market, By Region, From 2020 to 2025 (USD Million)
  11. Asia-Pacific Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  12. Asia-Pacific Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  13. Asia-Pacific Research institute Market, By Region, From 2020 to 2025 (USD Million)
  14. Asia-Pacific Diagnostics laboratories Market, By Region, From 2020 to 2025 (USD Million)
  15. Asia-Pacific Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  16. Asia-Pacific Medical Market, By Region, From 2020 to 2025 (USD Million)
  17. Asia-Pacific Experimental Market, By Region, From 2020 to 2025 (USD Million)
  18. Japan Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  19. Japan Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  20. Japan Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  21. Japan Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  22. China Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  23. China Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  24. China Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  25. China Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  26. India Antibodies Market, By Product type, From 2020 to 2025 (USD Million)
  27. India Antibodies Market, By Indication, From 2020 to 2025 (USD Million)
  28. India Antibodies Market, By End users, From 2020 to 2025 (USD Million)
  29. India Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  30. Asia-Pacific Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  31. Asia-Pacific Murine Market, By Region, From 2020 to 2025 (USD Million)
  32. Asia-Pacific Chimeric Market, By Region, From 2020 to 2025 (USD Million)
  33. Asia-Pacific Humanized Market, By Region, From 2020 to 2025 (USD Million)
  34. Asia-Pacific Human Market, By Region, From 2020 to 2025 (USD Million)
  35. Japan Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  36. China Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  37. India Antibodies Market, By Monoclonal Antibodies, From 2020 to 2025 (USD Million)
  38. Asia-Pacific Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  39. Asia-Pacific Type I Market, By Region, From 2020 to 2025 (USD Million)
  40. Asia-Pacific Type II Market, By Region, From 2020 to 2025 (USD Million)
  41. Asia-Pacific Type III Market, By Region, From 2020 to 2025 (USD Million)
  42. Asia-Pacific Type IV Market, By Region, From 2020 to 2025 (USD Million)
  43. Asia-Pacific Type V Market, By Region, From 2020 to 2025 (USD Million)
  44. Asia-Pacific Type VI Market, By Region, From 2020 to 2025 (USD Million)
  45. Asia-Pacific Type VII Market, By Region, From 2020 to 2025 (USD Million)
  46. Asia-Pacific Type VIII Market, By Region, From 2020 to 2025 (USD Million)
  47. Japan Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  48. China Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  49. India Antibodies Market, By Polyclonal Antibodies, From 2020 to 2025 (USD Million)
  50. Asia-Pacific Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  51. Asia-Pacific Immunogen Technology Market, By Region, From 2020 to 2025 (USD Million)
  52. Asia-Pacific Seattle Genetics Technology Market, By Region, From 2020 to 2025 (USD Million)
  53. Asia-Pacific Immunomedics technology Market, By Region, From 2020 to 2025 (USD Million)
  54. Japan Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  55. China Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  56. India Antibodies Market, By Antibody-Drug Complexes, From 2020 to 2025 (USD Million)
  57. Asia-Pacific Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  58. Asia-Pacific Western Blot Market, By Region, From 2020 to 2025 (USD Million)
  59. Asia-Pacific ELISA Market, By Region, From 2020 to 2025 (USD Million)
  60. Asia-Pacific Radioimmune Assays Market, By Region, From 2020 to 2025 (USD Million)
  61. Asia-Pacific immunofluorescence Market, By Region, From 2020 to 2025 (USD Million)
  62. Japan Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  63. China Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)
  64. India Antibodies Market, By Experimental, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample